Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis
We compared the efficacy and safety of low molecular weight heparins (LMWH) and unfractionated heparin (UFH) in the treatement of deep venous thrombosis (DVT). A comparison between two daily subcutaneous injections of LMWH against a single injection was also performed. DESIGN AN...
| Main Authors: | , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | eng |
| Published: |
Ferrata Storti Foundation
2012
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/23480 |
| _version_ | 1793400147991855104 |
|---|---|
| author | Rocha, E. (Eduardo) Martinez-Gonzalez, M.A. (Miguel Ángel) Montes, R. (Ramón) Panizo, C. (Carlos) |
| author_facet | Rocha, E. (Eduardo) Martinez-Gonzalez, M.A. (Miguel Ángel) Montes, R. (Ramón) Panizo, C. (Carlos) |
| author_sort | Rocha, E. (Eduardo) |
| collection | DSpace |
| description | We compared the efficacy and safety of low molecular
weight heparins (LMWH) and unfractionated heparin (UFH) in the treatement of deep
venous thrombosis (DVT). A comparison between two daily subcutaneous injections
of LMWH against a single injection was also performed. DESIGN AND METHODS: The
study was performed by a meta-analysis. Clot improvement in venography,
recurrency, total mortality and major hemorrhages were assessed in 4,472 patients
with DVT from 21 studies treated with subcutaneous LMWH or UFH. RESULTS: An
improvement in clot reduction (odds ratio 0.73, 95% confidence interval 0.59 to
0.90, p = 0.004), a decrease in total mortality (0. 68, 0.50 to 0.91, p = 0.012)
and a lower incidence of hemorrhage (0. 65, 0.43 to 0.98, p = 0.047) were
observed in LMWH treated patients. There were no differences in recurrences
(0.78, 0.59 to 1.04, p = 0. 10). A single dose of LMWH was better than two in
reducing major bleeding (c2 = 4.99, p = 0.025); however, the two dose regimen was
more effective in clot reduction (c2 = 8.56, p = 0.004). INTERPRETATION AND
CONCLUSIONS: LMWH is superior to UFH in terms of safety and efficacy. A single
daily dose of LMWH dose is a suitable therapeutic regimen and could facilitate
the outpatient treatment of venous thromboembolism. |
| format | info:eu-repo/semantics/article |
| id | oai:dadun.unav.edu:10171-23480 |
| institution | Universidad de Navarra |
| language | eng |
| publishDate | 2012 |
| publisher | Ferrata Storti Foundation |
| record_format | dspace |
| spelling | oai:dadun.unav.edu:10171-234802022-06-29T09:41:38Z Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis Rocha, E. (Eduardo) Martinez-Gonzalez, M.A. (Miguel Ángel) Montes, R. (Ramón) Panizo, C. (Carlos) Hemorrhage/chemically induced Heparin/standards/therapeutic use/toxicity Heparin, Low-Molecular-Weight/standards/therapeutic use/toxicity We compared the efficacy and safety of low molecular weight heparins (LMWH) and unfractionated heparin (UFH) in the treatement of deep venous thrombosis (DVT). A comparison between two daily subcutaneous injections of LMWH against a single injection was also performed. DESIGN AND METHODS: The study was performed by a meta-analysis. Clot improvement in venography, recurrency, total mortality and major hemorrhages were assessed in 4,472 patients with DVT from 21 studies treated with subcutaneous LMWH or UFH. RESULTS: An improvement in clot reduction (odds ratio 0.73, 95% confidence interval 0.59 to 0.90, p = 0.004), a decrease in total mortality (0. 68, 0.50 to 0.91, p = 0.012) and a lower incidence of hemorrhage (0. 65, 0.43 to 0.98, p = 0.047) were observed in LMWH treated patients. There were no differences in recurrences (0.78, 0.59 to 1.04, p = 0. 10). A single dose of LMWH was better than two in reducing major bleeding (c2 = 4.99, p = 0.025); however, the two dose regimen was more effective in clot reduction (c2 = 8.56, p = 0.004). INTERPRETATION AND CONCLUSIONS: LMWH is superior to UFH in terms of safety and efficacy. A single daily dose of LMWH dose is a suitable therapeutic regimen and could facilitate the outpatient treatment of venous thromboembolism. 2012-10-24T11:06:56Z 2012-10-24T11:06:56Z 2000 info:eu-repo/semantics/article https://hdl.handle.net/10171/23480 eng http://www.haematologica.org/content/85/9/935.long info:eu-repo/semantics/openAccess application/pdf Ferrata Storti Foundation |
| spellingShingle | Hemorrhage/chemically induced Heparin/standards/therapeutic use/toxicity Heparin, Low-Molecular-Weight/standards/therapeutic use/toxicity Rocha, E. (Eduardo) Martinez-Gonzalez, M.A. (Miguel Ángel) Montes, R. (Ramón) Panizo, C. (Carlos) Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis |
| title | Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis |
| title_full | Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis |
| title_fullStr | Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis |
| title_full_unstemmed | Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis |
| title_short | Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis |
| title_sort | do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? a meta-analysis |
| topic | Hemorrhage/chemically induced Heparin/standards/therapeutic use/toxicity Heparin, Low-Molecular-Weight/standards/therapeutic use/toxicity |
| url | https://hdl.handle.net/10171/23480 |
| work_keys_str_mv | AT rochaeeduardo dothelowmolecularweightheparinsimproveefficacyandsafetyofthetreatmentofdeepvenousthrombosisametaanalysis AT martinezgonzalezmamiguelangel dothelowmolecularweightheparinsimproveefficacyandsafetyofthetreatmentofdeepvenousthrombosisametaanalysis AT montesrramon dothelowmolecularweightheparinsimproveefficacyandsafetyofthetreatmentofdeepvenousthrombosisametaanalysis AT panizoccarlos dothelowmolecularweightheparinsimproveefficacyandsafetyofthetreatmentofdeepvenousthrombosisametaanalysis |